A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011

Pan African Medical Journal

Volumn 11, Issue , 2012, Pages 39-

  Dube, Nomathemba Michell ^a,b   Summers, Robert ^c   Tint, Khin San ^b   Mayayise, Guistee ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

Antiretroviral medicines; Human immunodeficiency virus; Pharmacovigilance; Surveillance

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; POLYNEUROPATHY; PRACTICE GUIDELINE; PRESCRIPTION; RISK FACTOR; SOUTH AFRICA; TREATMENT DURATION; TREATMENT INDICATION; AGED; EVALUATION; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS; TIME;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS; YOUNG ADULT;

EID: 84865288188     PISSN: 19378688     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Barth RE, Tempelman HA, Moraba R, Hoepelman AI. Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite early mortality. AIDS Res Treat. 2011; 2011: 434375. This article on PubMed
2. Statistics South Africa 2010 mid-year population estimates. 2010; Available from: http://www.statsa.gov.za/publications/P0302/P03022012.pdf. Accessed 10 February 2012
3. Torrs RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997 May 22; 336(21): 1531-2. This article on PubMed
4. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997; 349(9061): 1294. This article on PubMed
5. Hendrickson S, Jacobson LP, Nelson GW, Phair JP, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDSfree survival. J Acquir Immune Defic Syndr. 2008 Jul 1; 48(3): 263-71. This article on PubMed
6. World Health Organization. Pharmacovigilance. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/index.html. Accessed 10 January 2012
7. South African Department of Health. Operational Plan for Comprehensive HIV and AIDS Care, Management, and Treatment for South Africa. Pretoria, South Africa: Department of Health; 2003
8. World Health Organization. HIV drug resistance early warning indicators: World Health Organizations to monitor HIV drug resistance prevention at antiretroviral treatment sites. Available from: http://www.who.int/hiv/drugresistance. Accessed 10 January 2012
9. Coetzee D, Hildebrand K, Boulle A, Maartens G, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004; 18: 887-896. This article on PubMed
10. Rosen S, Ketlhapile M, Sanne I, De Silva MB. Characteristics of patients accessing care and treatment at public and nongovermental sites in South Africa. JIAPAC. 2008; 7(4): 200-7. This article on PubMed
11. National Library of Medicine. Drug Toxicity. Available from: http://en.citizendium.org/wiki/Drug_toxicity#cite_note-title-0. Accessed 10 January 2012
12. Epi Info™ Version 3.5.1. Available from: http://www.cdc.gov/
13. Stata, inventor Stata Statistical Software: Release 112009
14. Skovdal M, Campbell C, Madanhire C, Mupambireyi Z, et al. Masculinity as a barrier to men's use of HIV services in Zimbabwe. Globalization and Health. 2011; 7(13): 1-14. This article on PubMed
15. Muula AS, Ngulube TJ, Siziya S, Makupe C, et al. Gender distribution of adult patients on highly active antiretrovrial therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007 Apr 25; 7: 63. This article on PubMed
16. Dorrington R. Does the 2008 HSRC survey indicate a turning tide of HIV prevalence in children, teenagers and the youth?. SAMJ. 2009; 99(9): 631-633. This article on PubMed
17. Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up-contributing factors and challenges in South African patients on antiretroviral therapy. SAMJ. 2007; 97(9): 853-857. This article on PubMed
18. Miller C, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1: 48-54. This article on PubMed
19. Dahab M, Charalambous S, Hamilton R. "That is why I stopped the ART": Patients' and provider perspectives of barriers to and enablers of HIV treatment adherance in a South African workplace program. BMC Public Health. 2008 Feb 18; 8: 63. This article on PubMed
20. LiddyJC. Stavudine 20 mg BID or less versus stavudine 30 mg BID or more as a component of combination antiretroviral therapy for HIV. 2008. Available from: http://www.who.int/hiv/topics/treatment/stavudine_art.pdf. Accessed 10 January 2012
21. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. World Health Organization. 2002
22. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337: 734-739. This article on PubMed
23. Hammer SM KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337: 725-733. This article on PubMed
24. Rajesh R, Vidyasagar S, Nandakumar K. Highly active antiretroviral therapy induced adverse drug reactions in Indian human immunodeficiency virus positive patients. Pharmacy Practice (Internet). 2010; 9(1): 48-55